R&D Deep Dive: R&D Innovation In this issue of Deep Dive we look at innovation in pharma R&D, asking how can pharmaceutical companies change up the development model with new strategies and technologies to cut waste
News Chiesi signs $1.9bn deal to buy KalVista and its HAE drug Chiesi has boosted its rare disease business with an agreement to buy KalVista and Ekterly, its oral drug for treating attacks in rare disease HAE.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.